TABLE 1.

BLEB SURVIVAL TIME OF THE SEQUENTIAL MULTITREATMENT GROUP COMPARED TO THE SIX INDIVIDUAL SINGLE-THERAPY GROUPS FROM PART 1 OF THE STUDY, AND TO CONTROL GROUPS

GROUP	MEAN DIFFERENCE (GROUP MEAN − MULTITREATMENT GROUP MEAN)	SE	TVALUE	PVALUE
Negative control (BSS)	−12.2	0.54	−22.8	<.0001
CTGF antisense	−4.70	0.59	−7.9	<.0001
CTGF antibody	−3.45	0.59	−5.8	<.0001
TGF-β2 antisense	−8.45	0.59	−14.2	<.0001
TGF-β2 antibody	−8.95	0.59	−15.1	<.0001
M-6-P	−9.95	0.59	−16.8	<.0001
Ilomastat	−2.20	0.65	−3.4	.0019
Mitomycin-C	7.30	0.54	13.6	<.0001

BSS = balanced saline solution; M-6-P = mannose-6-phosphate; SE = standard error of the mean.